LLY

736.61

+0.51%↑

JNJ

177.74

-0.07%↓

ABBV

211.72

+0.02%↑

UNH

307.43

-0.44%↓

AZN

82.11

+2.45%↑

LLY

736.61

+0.51%↑

JNJ

177.74

-0.07%↓

ABBV

211.72

+0.02%↑

UNH

307.43

-0.44%↓

AZN

82.11

+2.45%↑

LLY

736.61

+0.51%↑

JNJ

177.74

-0.07%↓

ABBV

211.72

+0.02%↑

UNH

307.43

-0.44%↓

AZN

82.11

+2.45%↑

LLY

736.61

+0.51%↑

JNJ

177.74

-0.07%↓

ABBV

211.72

+0.02%↑

UNH

307.43

-0.44%↓

AZN

82.11

+2.45%↑

LLY

736.61

+0.51%↑

JNJ

177.74

-0.07%↓

ABBV

211.72

+0.02%↑

UNH

307.43

-0.44%↓

AZN

82.11

+2.45%↑

Search

Novo Nordisk A-S

Suletud

SektorTervishoid

56.76 0.71

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

56.36

Max

57.34

Põhinäitajad

By Trading Economics

Sissetulek

-2.5B

27B

Müük

-1.2B

77B

P/E

Sektori keskmine

14.514

35.733

Aktsiakasum

6.53

Dividenditootlus

3.06

Kasumimarginaal

34.484

Töötajad

78,387

EBITDA

-2.5B

44B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+19.85% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.06%

3.13%

Turustatistika

By TradingEconomics

Turukapital

33B

249B

Eelmine avamishind

56.05

Eelmine sulgemishind

56.76

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

Novo Nordisk A-S Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. aug 2025, 13:52 UTC

Suurimad hinnamuutused turgudel

GoodRx Partners With Novo Nordisk to Lower Cost of Weight-Loss Drugs

18. aug 2025, 09:23 UTC

Suurimad hinnamuutused turgudel

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

18. aug 2025, 09:23 UTC

Suurimad hinnamuutused turgudel

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

6. aug 2025, 06:52 UTC

Tulu

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues -- Update

6. aug 2025, 06:21 UTC

Tulu

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues

2. sept 2025, 09:14 UTC

Kuumad aktsiad

Stocks to Watch Tuesday: Nestlé, Novo Nordisk, Nvidia -- WSJ

21. aug 2025, 08:49 UTC

Tulu
Kuumad aktsiad

Stocks to Watch Thursday: Meta, Coty, Walmart, Novo Nordisk -- WSJ

18. aug 2025, 09:23 UTC

Kuumad aktsiad

Stocks to Watch Monday: Novo Nordisk, Soho House, UnitedHealth -- WSJ

8. aug 2025, 05:32 UTC

Market Talk

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

7. aug 2025, 11:32 UTC

Tulu

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7. aug 2025, 11:03 UTC

Tulu

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7. aug 2025, 10:41 UTC

Tulu

Eli Lilly Stock Drops on Weight-Loss Pill Data Ahead of Earnings -- Barrons.com

6. aug 2025, 20:34 UTC

Tulu

Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday -- Barrons.com

6. aug 2025, 08:45 UTC

Tulu

Novo Nordisk to Cut Costs After Stock Slump. Why Earnings Failed to Impress. -- Barrons.com

6. aug 2025, 07:19 UTC

Market Talk
Tulu

Novo Nordisk Sales in Line, Boosted by One-Off Rebate -- Market Talk

6. aug 2025, 05:50 UTC

Tulu

Novo Nordisk: Gudiance Assumes Macroeconomic, Political Environment Won't Significantly Change Business Conditions During 2025

6. aug 2025, 05:48 UTC

Tulu

Novo Nordisk Declares Interim Dividend of DKK3.75 Vs DKK3.50

6. aug 2025, 05:46 UTC

Tulu

Novo Nordisk Will Continue to Invest in Expanding Direct-to-Patient Initiatives For Wegovy

6. aug 2025, 05:38 UTC

Tulu

Novo Nordisk 2Q Ozempic Drug Sales DKK31.8B Vs DKK28.88B

6. aug 2025, 05:37 UTC

Tulu

Novo Nordisk 2Q Wegovy Drug Sales DKK19.53B Vs DKK11.66B

6. aug 2025, 05:36 UTC

Tulu

Novo Nordisk 2Q Gross Margin 83.3% Vs 84.9%, Op Margin 43.5% Vs 38.1%

6. aug 2025, 05:35 UTC

Tulu

Novo Nordisk: Taking Measures to Sharpen Commercial Execution Further, Ensure Efficiencies in Cost Base

6. aug 2025, 05:34 UTC

Tulu

Novo Nordisk: Continues Global Rollout of Wegovy to More Markets, Investing in Commercial Activities

6. aug 2025, 05:31 UTC

Tulu

Novo Nordisk 2Q Net Pft DKK26.5B

6. aug 2025, 05:31 UTC

Tulu

Novo Nordisk 2Q Oper Pft DKK33.45B

6. aug 2025, 05:31 UTC

Tulu

Novo Nordisk 2Q Sales DKK76.86B

5. aug 2025, 21:58 UTC

Tulu

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5. aug 2025, 17:26 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Hims & Hers Had a Tough Quarter. Weight-Loss Drugs Are Only One Problem. -- Barrons.com

5. aug 2025, 15:15 UTC

Tulu

Novo Nordisk Stock Catches a Downgrade. The Eli Lilly Threat Is Just One Reason. -- Barrons.com

5. aug 2025, 10:07 UTC

Market Talk

Novo Nordisk's Facing Challenging Times -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Novo Nordisk A-S Prognoos

Hinnasiht

By TipRanks

19.85% tõus

12 kuu keskmine prognoos

Keskmine 67.57 USD  19.85%

Kõrge 90 USD

Madal 50 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Novo Nordisk A-S 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

7 ratings

2

Osta

5

Hoia

0

Müü

Tehniline skoor

By Trading Central

62.63 / 69.23Toetus ja vastupanu

Lühikene perspektiiv

Weak Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.